Tan Jiaxiong, Huang Shuxin, Huang Jingying, Yu Zhi, Chen Youchun, Lu Yuhong, Li Yangqiu, Chen Shaohua
Department of Hematology, First Affiliated Hospital, Jinan University, Guangzhou, China.
Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, China.
Asia Pac J Clin Oncol. 2020 Jun;16(3):137-141. doi: 10.1111/ajco.13304. Epub 2020 Feb 7.
To characterize the distribution of T cell immunoglobulin mucin-domain-containing-3 (Tim-3) within the exhausted T cells in patients with newly diagnosed acute myeloid leukemia (AML) and AML in complete remission.
Tim-3 expression and coexpression with PD-1, CD244, and CD57 in CD3+, CD4+, and CD8+T cells were analyzed by multicolored fluorescent flow cytometry in peripheral blood from 28 newly diagnosed, untreated AML patient and 12 cases with AML in complete remission, 23 healthy individuals served as control.
Increasing Tim-3+CD244+ and Tim-3+CD57+ in CD3+, CD4+, and CD8+ T cells were found in AML and AML-CR groups in comparison with healthy controls. Similarly, increasing Tim-3 coexpression PD-1+ CD3+/CD4+/CD8+ T cells were found in AML group. A high tendency of PD-1+Tim-3+CD3+/CD4+/CD8+ T cells was detected in the AML-M4 subtype group followed by the M2 group, and a low tendency was found in the M3 group. Moreover, Tim-3+CD244+CD8+ T cells were found to be significantly higher in the M4 than that in M3 group. Dynamic changes of Tim-3+ T cells in AML patients who achieved CR after chemotherapy at different time points showed that Tim-3+ T cell subsets were evidently decreased; however, they remained at a higher level in most AML-CR patients.
We made a novel observation on distribution of Tim-3+CD244+, Tim-3+CD57+, and Tim-3+PD-1+ T cells in patients with AML. Chemotherapy is incapable of resolving immunosuppression in some cases with AML in CR status.
描述新诊断的急性髓系白血病（AML）患者及完全缓解的AML患者中，含T细胞免疫球蛋白黏蛋白结构域3（Tim-3）在耗竭T细胞内的分布情况。
采用多色荧光流式细胞术分析28例新诊断、未治疗的AML患者及12例完全缓解的AML患者外周血中CD3⁺、CD4⁺和CD8⁺T细胞中Tim-3的表达及其与PD-1、CD244和CD57的共表达情况，23名健康个体作为对照。
与健康对照相比，AML组和AML完全缓解（AML-CR）组中CD3⁺、CD4⁺和CD8⁺T细胞中Tim-3⁺CD244⁺和Tim-3⁺CD57⁺细胞增多。同样，AML组中Tim-3与PD-1共表达的CD3⁺/CD4⁺/CD8⁺T细胞也增多。在AML-M4亚型组中检测到PD-1⁺Tim-3⁺CD3⁺/CD4⁺/CD8⁺T细胞的比例较高，其次是M2组，M3组比例较低。此外，发现M4组中Tim-3⁺CD244⁺CD8⁺T细胞明显高于M3组。化疗后达到完全缓解的AML患者在不同时间点Tim-3⁺T细胞的动态变化表明，Tim-3⁺T细胞亚群明显减少；然而，大多数AML-CR患者中Tim-3⁺T细胞仍处于较高水平。
我们对AML患者中Tim-3⁺CD244⁺、Tim-3⁺CD57⁺和Tim-3⁺PD-1⁺T细胞的分布有了新的观察结果。化疗在某些AML完全缓解状态的病例中无法解决免疫抑制问题。
